Evidence map›Paper›PMID 39847064›Full record

ArticleClinical neuroradiology2025

Treatment of Intracranial Aneurysms with the FRED X Flow Diverter Stent: Mid-term Angiographic and Safety Results.

David W Wen, James Ayre, Mani Puthuran, Paul Maliakal, Souhyb Masri, Richard Pullicino, Aubrey Smith, Feyi Babatola, Gilbert Gravino, Nasr Abdelsalam and 2 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Clinical neuroradiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Short to mid-term outcomes of flow re-direction endoluminal device X (FREDDiagnostic and interventional radiology (Ankara, Turkey) · 2026
    Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

David W WenDepartment of Neuroradiology, The Walton Centre for Neurology and Neurosurgery, Liverpool, UK. david.wen.w@singhealth.com.sg.ORCID http://orcid.org/0000-0001-7096-6327
James AyreDepartment of Diagnostic and Interventional Neuroradiology, Hull Royal Infirmary, Hull, UK.
Mani PuthuranDepartment of Neuroradiology, The Walton Centre for Neurology and Neurosurgery, Liverpool, UK.
Paul MaliakalDepartment of Diagnostic and Interventional Neuroradiology, Hull Royal Infirmary, Hull, UK.
Souhyb MasriDepartment of Neuroradiology, The Walton Centre for Neurology and Neurosurgery, Liverpool, UK.
Richard PullicinoDepartment of Neuroradiology, The Walton Centre for Neurology and Neurosurgery, Liverpool, UK.
Aubrey SmithDepartment of Diagnostic and Interventional Neuroradiology, Hull Royal Infirmary, Hull, UK.
Feyi BabatolaDepartment of Neuroradiology, The Walton Centre for Neurology and Neurosurgery, Liverpool, UK.
Gilbert GravinoDepartment of Neuroradiology, The Walton Centre for Neurology and Neurosurgery, Liverpool, UK.
Nasr AbdelsalamDepartment of Neuroradiology, The Walton Centre for Neurology and Neurosurgery, Liverpool, UK.
Hamed NejadhamzeeigilaniDepartment of Diagnostic and Interventional Neuroradiology, Hull Royal Infirmary, Hull, UK.
Arun ChandranDepartment of Neuroradiology, The Walton Centre for Neurology and Neurosurgery, Liverpool, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe aim of our study was to assess the mid-term efficacy and safety of the FRED X flow diverting stent (FDS) in the treatment of intracranial aneurysms. The FRED X FDS is relatively new with limited data on its longer-term effectiveness and safety profile.

methodsPatients with intracranial aneurysms treated with the FRED X FDS at two UK centres, between March 2021 and July 2022 with at least 18 months follow-up, were retrospectively reviewed. Clinical, procedural and imaging data was analyzed.

resultsTwenty-two patients with 24 aneurysms treated with the FRED X device, and had completed at least 18 months of follow-up, were included in this study. The rate of complete aneurysm occlusion (Raymond-Roy Class I) was 83.3% at a mean follow-up duration of 21.5 months. One case of major adverse event (4.3%) related to a post-procedural stroke which is also the only case of permanent neurological deficit (4.3%) in our cohort. Three cases of minor adverse events (13.0%) and 2 cases of asymptomatic adverse events (8.7%) were also recorded.

conclusionUse of the FRED X FDS to treat intracranial aneurysms has acceptable safety profile and efficacy in the mid-term.

Indexed as

Cerebral AngiographyEndovascular ProceduresIntracranial AneurysmStentsAdultAgedFemaleHumansMaleMiddle AgedRetrospective StudiesTreatment OutcomeAneurysmEndovascularFlow diverterNeurointerventionStent

Identifiers

PMID39847064

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.